News

August 3, 2023
IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif. , Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company
Additional Formats
June 21, 2023
IGM Announces Proposed Public Offering and Concurrent Private Placement
MOUNTAIN VIEW, Calif. , June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in
Additional Formats
June 1, 2023
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif. , June 01, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will participate in a fireside chat at
Additional Formats
Displaying 1 - 10 of 19